Vigil Neuroscience (NASDAQ:VIGL – Get Free Report)‘s stock had its “outperform” rating reiterated by equities researchers at Wedbush in a report released on Wednesday, Benzinga reports. They currently have a $22.00 price objective on the stock.
A number of other equities research analysts have also issued reports on VIGL. HC Wainwright reiterated a “buy” rating and issued a $24.00 target price on shares of Vigil Neuroscience in a research note on Wednesday. JMP Securities restated a “market outperform” rating and issued a $23.00 target price on shares of Vigil Neuroscience in a research note on Thursday, April 18th.
Check Out Our Latest Report on VIGL
Vigil Neuroscience Stock Performance
Vigil Neuroscience (NASDAQ:VIGL – Get Free Report) last posted its quarterly earnings data on Tuesday, March 26th. The company reported ($0.57) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.01). Sell-side analysts expect that Vigil Neuroscience will post -2.56 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in Vigil Neuroscience stock. Strs Ohio acquired a new stake in Vigil Neuroscience, Inc. (NASDAQ:VIGL – Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 8,200 shares of the company’s stock, valued at approximately $27,000. 83.64% of the stock is currently owned by institutional investors and hedge funds.
Vigil Neuroscience Company Profile
Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.
Further Reading
- Five stocks we like better than Vigil Neuroscience
- What Are Dividends? Buy the Best Dividend Stocks
- PulteGroup Wins and Wins More on Interest Rate Cuts
- Buy P&G Now, Before It Sets A New All-Time High
- How to Read an Earnings Report | Step by Step Guide with Tips
- Investing in the High PE Growth Stocks
- Datadog: In the Doghouse or Pullback to the Buyzone?
Receive News & Ratings for Vigil Neuroscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vigil Neuroscience and related companies with MarketBeat.com's FREE daily email newsletter.